Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place March 29 to April 2, 2025 in Chicago, Illinois, U.S.
Details for the oral presentation can be found below:
Title: Brilaroxazine Phase 3 Recover 52-Week Open-Label Evaluation of Efficacy and Safety over 12 Months in Stable Schizophrenia Participants
Session: Pharmaceutical Pipeline
Date and Time: Sunday, March 30th from 10:30 AM – 12:00 PM ET CST
Presenter: Dr. Laxminarayan Bhat, Founder & CEO, Reviva Pharmaceuticals
Abstracts and additional details can be found at the SIRS 2025 website.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.